Navigation Links
Pharmacyclics, Inc. Prices Public Offering of Common Stock
Date:3/8/2013

SUNNYVALE, Calif., March 8, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC), a clinical stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases, today announced the pricing of a previously announced underwritten registered public offering of 2,200,000 shares of its common stock, representing approximately 3.1% of the shares of common stock currently outstanding, at a public offering price of $94.20 per share. All of the shares are being sold by Pharmacyclics. The offering is expected to close on March 13, 2013, subject to customary closing conditions.

J.P. Morgan Securities LLC is acting as sole manager for the offering. Pharmacyclics has granted the underwriter a 30-day option to purchase up to an additional 330,000 shares of common stock to cover over-allotments, if any.

Pharmacyclics intends to use the net proceeds from this offering to accelerate commercial readiness for Ibrutinib post Breakthrough Therapy Designation, to advance its clinical pipeline, including expanding clinical development of Ibrutinib in additional indications, to evaluate strategic opportunities to potentially add synergistic assets, and for general corporate purposes.

The shares will be issued pursuant to an automatic shelf registration statement on Form S-3 previously filed with the Securities and Exchange Commission, Registration No. 333-187104. A preliminary prospectus supplement related to the offering has been filed with the Securities and Exchange Commission. A final prospectus supplement related to the offering will be filed with the Securities and Exchange Commission.

This announcement shall not constitute an offer to sell or the solicitation of an offer to buy any securities of Pharmacyclics, nor shall there be any offer or sale of securities in any state or jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Copies of the final prospectus supplement, when available, and accompanying prospectus may be obtained from J.P. Morgan Securities LLC via Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York, 11717 or by calling toll-free (866) 803-9204.

About Pharmacyclics

Pharmacyclics, Inc., headquartered in Sunnyvale, California, is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Its corporate mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious medical healthcare needs; and to identify promising product candidates based on scientific and administrational development expertise, develop our product candidates in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.

Presently, Pharmacyclics has three product candidates in clinical development and several research molecules in lead optimization. The Company is committed to high standards of ethics, scientific rigor, and operational efficiency as it moves each of these programs toward viable commercialization.


'/>"/>
SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
2. Inovio Pharmaceuticals Prices $15.1 Million Offering of Common Stock and Warrants
3. Novelos Therapeutics Prices $5.5 Million Public Offering
4. Accuray Prices Offering Of $100 Million Of 3.50% Convertible Senior Notes
5. Volcano Corporation Prices Offering Of $400 Million 1.75% Convertible Senior Notes Due 2017
6. Cynosure, Inc. Prices Public Offering of Class A Common Stock
7. Isis Pharmaceuticals Prices Offering of $201.25 Million of 2 3/4% Convertible Senior Notes, Including Exercise in Full of Over-Allotment Option
8. Solta Medical, Inc. Prices $15 Million Public Offering of Common Stock
9. MAP Pharmaceuticals, Inc. Prices Public Offering of Common Stock
10. Omeros Prices $30 Million Public Offering of Common Stock
11. Novelos Therapeutics Prices $5.4 Million Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... 28, 2016  While Abbott,s announced purchase of ... valve repair and stent business, healthcare research firm ... more firmly into patient monitoring.  Kalorama said that ... device areas, with double-digit growth expected the next ... Advanced Remote Patient Monitoring . Abbott Laboratories ...
(Date:4/28/2016)... 28, 2016 ... Phillips und Stephen Schmidt ... ArisGlobal®, ein führender Anbieter cloudbasierter Softwarelösungen ... bekannt, dass neue Führungskräfte zum Team Sicherheit ... die vielfältige Erfahrungen mitbringen.  Dies wird die ...
(Date:4/28/2016)... April 28, 2016 , Net Sales of ... basis over the prior year period, and an increase of ... , Diluted EPS for the first quarter were $0.52 reported, ... $2.00 adjusted, an increase of 29.9% over the prior year ... adjusted earnings guidance for 2016 Zimmer Biomet Holdings, ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... ... Celiac Association (CCA), is pleased to announce the launch of the GFCP ... articles, recipes, and more. The purpose of the GFCP Scoop site ...
(Date:4/29/2016)... ... April 29, 2016 , ... New York City based oral and maxillofacial surgeon Dr. ... very effective way to treat obstructive sleep apnea. Dr. Jamali is proud to offer this ... procedure that involves one or both jaw bones. This surgery is performed to correct the ...
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, the ... of funding led by Eastside Partners, with participation from existing investor Martin Ventures. ... base and accelerate its technology and product roadmap. , “Jvion is ...
(Date:4/29/2016)... ... April 29, 2016 , ... CURE ... entirely on patients with cancer, today announced that Lynne Malestic, RN, of Eisenhower ... 2016 CURE® Extraordinary Healer® for Oncology Nursing , which honors nurses who have ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... to promote their animal line of probiotics, Petbiotics ™, as they fondly ... turnout of animal rescue groups networking for their non-profit organizations. Animal rescues across ...
Breaking Medicine News(10 mins):